Table 3.
Ex vivo results
| HV | sCAD | aCAD | |
|---|---|---|---|
| (n = 35) | (n = 35) | (n = 35) | |
| IL-6 | |||
| LPS | 797.7 (1.9) | 933.5 (2.0) | 62.1 (6.5) |
| ETC-216* | 15.8 (2.9) | 9.5 (3.6) | 3.8 (4.0) |
| MDCO-216 | 0.8 (1.9) | 0.7 (1.5) | 1.0 (2.0) |
| TNF-α | |||
| LPS | 117.4 (1.9) | 242.0 (1.8) | 46.9 (4.0) |
| ETC-216* | 9.0 (2.8) | 6.0 (3.8) | 3.5 (4.0) |
| MDCO-216 | 0.8 (1.8) | 0.7 (1.9) | 1.0 (2.0) |
Geometric mean (standard deviation) of ratios of LPS, ETC-216 and MDCO-216 stimulated cytokine concentration over unstimulated (background) levels for IL-6 and TNF-α
*Ratios are underestimated as a result of stimulated samples being >ULOQ: for IL-6 in 26 (74.3%) HV, 19 (54.3%) sCAD, 16 (45.7%) aCAD; and for TNF-α in 20 (57.1%) HV, 24 (68.6%) sCAD, 6 (17.1%)
aCAD Patients with acute coronary artery disease (CAD); HV Healthy volunteers; LPS Lipopolysaccharide; sCAD Patients with stable coronary artery disease (CAD); ULOQ Upper limit of quantitation